ReviewDrug safety2019
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.
Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this papercites it
ReviewDrug safety2019
Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.